• 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br MM or CSR It has been reported


    MM or CSR. It has been reported rituximab treatment resulted in a significant clinical improvement in LEMS [26]. One patient in our study gained the status of MM-3 after rituximab treatment with QMG score dropping from 18 to 2 in 6 months.
    In conclusion, patients with SCLC-LEMS tended to take less time to make the diagnosis and have a higher prevalence of ataxia com-paring with NT-LEMS. In SCLC patients, those with LEMS showed a favorable prognosis according to their survival time. Most NT-LEMS showed improvement or obtained CSR/PR/MM after immunosuppressive treatment.
    This work was supported by the National key Research and Development Program of China (No. 2016YFC0901504).
    The authors declare no conflicts of interest.
    Appendix A. Supplementary material
    [1] Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098–107.
    [3] Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003;53:21–8.
    [4] Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250:698–701. [5] Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel Temozolomide in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–74.
    [6] Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35–42. 
    [7] Oh SJ, Kurokawa K, Claussen GC, Ryan HFJ. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515–20.
    [15] Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003;53:270–3.
    [16] Wirtz PW, Sotodeh M, Nijnuis M, Van Doorn PA, Van Engelen BG, Hintzen RQ, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73:766–8.
    [17] Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL. Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 2017;56:421–6. [18] Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117–8.
    [19] Wirtz PW, Lang B, Graus F, van den Maagdenberg AM, Saiz A, de Koning GPA, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005;164:161–5.
    [20] Liu X, Jiang T, Li W, Li X, Zhao C, Shi J, et al. Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer. Lung Cancer 2018;115:109–15. [21] Cai Q, Luo HL, Gao XC, Xiong CJ, Tong F, Zhang RG, et al. Clinical features and prognostic factors of small cell lung cancer: a osmoregulators retrospective study in 148 patients. J Huazhong Univ Sci Technol Med Sci 2016;36:916–22. [22] Liu S, Guo H, Kong L, Li H, Zhang Y, Zhu H, et al. The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute. Int J Clin Exp Pathol 2015;8:11033–41. [23] Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2017;88:1334–9.
    [24] Hulsbrink R, Hashemolhosseini S. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy. Clin Neurophysiol 2014;125:2328–36. [25] Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44–8. [26] Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671–3. Original Study